A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.

Clin Cancer Res · 2025 · PMC12163594 · PMID 40152791

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an unexpected trendno p-value reported

The analysis of baseline TMB in patients from both combination arms revealed an unexpected trend because all patients with high TMB had PD, whereas the two PR patients had low/intermediate scores.

also in 86 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.